Clinical Trials Browser

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Small Cell, Small Cell Lung Carcinoma

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Neoplasm Metastasis

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

Urinary Bladder Neoplasms, Lung Neoplasms

Lung Neoplasms, Small Cell Lung Carcinoma

Triple Negative Breast Neoplasms

Glioblastoma

Carcinoma, Transitional Cell

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Head and Neck Neoplasms

Salivary Gland Neoplasms

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms

Metastatic Urothelial Cancer

Breast Neoplasms

Urothelial Bladder Carcinoma

Localized Muscle Invasive Bladder Urothelial Carcinoma

Breast Neoplasms

Ovarian Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms

Breast Neoplasms

Cholangiocarcinoma, Klatskin Tumor

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Endometrial Neoplasms

Triple Negative Breast Neoplasms

Neoplasm Metastasis, Liver Failure

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Triple Negative Breast Neoplasms

Neoplasm Metastasis

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Advanced Breast Cancer

Clinical Trials

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

InCITe

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

ASCENT-03

Sacituzumab Govitecan in Recurrent Glioblastoma

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

TianjinCIH

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

EVOKE-SCLC-04

VELOCITY-Lung

Morpheus-panBC

TROPHY U-01

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

SIMONE

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

EVOKE-02

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

TROPiCS-03

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

SATROPIN

STORM

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

ADJUNCT

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC